ExpreS2ion Biotech (EXPRS2) Økonomisk Ugebrev Life Science Investor Conference summary

Key presentations and insights

• Highlighted a first-in-class HER2 immunotherapy (ES2B-C001) showing durable immune control in HER2-driven cancers, with promising preclinical and early clinical results.

• Emphasized the unmet need in breast cancer, noting resistance and limited durability of current therapies, and the opportunity for improved immunotherapy.

• Detailed the proprietary Expres2 protein manufacturing platform, validated in Phase III and used in multiple vaccine and biologic programs.

• Outlined a broad pipeline including oncology and infectious disease projects, with several programs supported by partnerships and non-dilutive funding.

Clinical and market developments

• Phase I trial of ES2B-C001 in advanced HER2-positive/low breast cancer patients showed no safety concerns and robust antibody responses; Phase Ia data expected mid-2026, Phase Ib by end-2026.

• HER2-targeted therapies exceeded €17B in global sales in 2024, with an estimated addressable opportunity over €5B for new entrants.

• Development strategy targets out-licensing after Phase II proof-of-concept, with potential for earlier deals if strong signals emerge.

• Upcoming catalysts include multiple clinical readouts, manufacturing milestones, and potential licensing events over the next 12–18 months.

Financial and organizational updates

• Announced a rights issue of ~53m SEK (about 60% secured) to fund Phase I completion, R&D, contract research growth, and co-finance grant projects.

• Leadership team and board bring extensive clinical, financial, and licensing experience, supporting execution through Phase II.

• Strategic position includes 34% ownership in AdaptVac and a CRO services business, with a presence on Nasdaq First North since 2016.